TransCode Therapeutics (RNAZ)
(Delayed Data from NSDQ)
$0.26 USD
+0.01 (2.41%)
Updated Sep 13, 2024 03:59 PM ET
After-Market: $0.26 0.00 (0.35%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Price, Consensus and EPS Surprise
RNAZ 0.26 +0.01(2.41%)
Will RNAZ be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RNAZ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RNAZ
Beat the Market Like Zacks: Goldman Sachs, Micron, Amgen in Focus
TransCode (RNAZ) Down 50% on Issue of New Common Stock
RNAZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
TransCode Therapeutics Inc. (RNAZ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Other News for RNAZ
Transcode Therapeutics announces publication of study on TTX-MC138
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate?s Preclinical Efficacy Against Metastatic Cancer
Buy Rating for TransCode Therapeutics Backed by NIH Grant and Promising Treatment Efficacy
TransCode Therapeutics secures $2M grant for lead candidate
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate